Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Uterine Bleeding, Uterine Fibroids, Adenomyosis
Interventions
Evaluation of MRI, US for pelvic and uterine conditions, Patient preference between MRI and Ultrasound
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed No phase listed Observational

Fibroid Growth Study

NCT00340288
Conditions
Uterine Leiomyomas
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated No phase listed Observational

South Miami Hospital Fibroid Registry

NCT02362009
Conditions
Uterine Myomas, Leiomyomas, or Fibromas
Interventions
Not listed
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix + Estradiol + Norethindrone Acetate
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts
Conditions
Leiomyoma
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
University of Miami
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Fibroids, Uterine, Fluid Deficit, Hysteroscopy / Methods
Interventions
Misoprostol Tabets, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Conditions
Uterine Fibroids
Interventions
Not listed
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Irvine, California
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

NCT04311073
Conditions
Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions
Tranexamic Acid, Placebos
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Fibroid Uterus, Gynecologic Disease, Leiomyoma, Uterine
Interventions
Carboprost Tromethamine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leiomyoma
Interventions
ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Uterine Fibroids
Interventions
Placebo, Telapristone Acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Conditions
Uterine Fibroid
Interventions
Body System - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
Terminated Not applicable Interventional Results available

Embozene Microspheres for Uterine Fibroid Embolization (UFE)

NCT01675011
Conditions
Uterine Fibroids
Interventions
Embozene® Microspheres, Embosphere®
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Albany, New York • New Hyde Park, New York
Conditions
Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions
Treatment with HydroPearl via radial access
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344
Conditions
Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions
Standard, Standard-vaginal misoprostol
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1,130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hysterectomy
Interventions
Peritoneal washings
Diagnostic Test
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Completed Not applicable Interventional Results available

HOME Study: Hysteroscopic Office Myomectomy Evaluation

NCT01152112
Conditions
Uterine Fibroids, Polyps
Interventions
Myomectomy
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Boulder, Colorado • Champaign, Illinois + 6 more
Completed No phase listed Observational Accepts healthy volunteers

Biologic Predictors of Leiomyoma Treatment Outcomes

NCT01936493
Conditions
Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
DNA analysis, Hormonal analysis
Genetic · Other
Lead sponsor
Elizabeth A. Stewart
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota